Evidence map›Paper›PMID 35844738›Full record

ArticleFrontiers in pediatrics2022

Case Report: The Value of Genomic Analysis in a Case of Megakaryoblastic Leukemia With Atypical Initial Manifestation.

Miriam Gutiérrez-Jimeno, Elena Panizo-Morgado, Marta Calvo-Imirizaldu, Víctor Galán-Gómez, Adela Escudero-López, Ana Patiño-García

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm.Virchows Archiv : an international journal of pathology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Miriam Gutiérrez-JimenoDepartment of Pediatrics, University Clinic of Navarra, Pamplona, Spain.
Elena Panizo-MorgadoDepartment of Pediatrics, University Clinic of Navarra, Pamplona, Spain.
Marta Calvo-ImirizalduDivision of Neuroradiology, Department of Radiology, University Clinic of Navarra, Pamplona, Spain.
Víctor Galán-GómezPediatric Hematology and Oncology Unit, Department of Pediatrics, La Paz University Hospital, Madrid, Spain.
Adela Escudero-LópezPediatric Molecular Hemato-Oncology Section, Department of Genetics, Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital-IdiPAZ, Madrid, Spain.
Ana Patiño-GarcíaDepartment of Pediatrics, University Clinic of Navarra, Pamplona, Spain.
Clinica Universidad de Navarra · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 7-month-old female patient who developed acute megakaryoblastic leukemia 6 months after the appearance of skull bone lesions. Initial evaluation and diagnosis of this patient were challenging and only achieved thanks to genomic analysis by NGS (next generation sequencing). It is unusual for the initial manifestation of acute megakaryoblastic leukemia to be a skull bone lesion. Extramedullary acute myeloid leukemia (eAML), also known as myeloid sarcoma (MS), often occurs simultaneously with acute myeloid leukemia (AML), although it may precede AML. Genomic analysis based on a NGS panel (Oncomine Childhood Cancer Research Assay) detected a

Indexed as

acute megakaryoblastic leukemiaextramedullary acute myeloid leukemiagenomicsmyeloid sarcomanext generation sequencing

Identifiers

PMID35844738
PMCPMC9277000
OpenAlexW4283688239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.